Literature DB >> 25007136

The immunophenotype of bone marrow lymphocytes in children with immune thrombocytopenic purpura.

Samin Alavi1, Zahra Aryan, Farid Ghazizadeh, Nahid Arabi, Mahin Nikougoftar, Maryam Ebadi.   

Abstract

PURPOSE: Primary immune thrombocytopenic purpura (ITP), caused by immune system dysfunction, is recognized as the leading cause of thrombocytopenia in pediatric population. Nonetheless, inadequate studies have been performed on bone marrow immunophenotyping of children with ITP. In this study, we aimed to investigate the immunophenotype of bone marrow lymphocytes in these children. PATIENTS AND METHODS: Between 2008 and 2012, 35 children with ITP and 26 age and sex matched healthy controls were recruited. All participants underwent bone marrow aspiration. Appropriate B-cell, T-cell, and myeloid lineage monoclonal antibodies were employed to determine the immunophenotype of these patients.
RESULTS: CD10, CD19, and CD20, all indicative of premature B-cell markers, were significantly greater in children with ITP. CD22, mainly expressed on mature B cells was slightly, but not significantly reduced in the patients' group (P = .42). On the other hand, T cell markers including CD2, CD3, CD5, and CD7 were underexpressed. CD33, a specific marker for myeloid lineage, was underexpressed in the patients' group (5.6 ± 4.7 vs. 12.9 ± 7.3, P < .001). Noteworthy, the immunophenotype did not significantly differ between acute and persistent cases.
CONCLUSION: Overall, a phenotype characterized by increased pre-B-cell markers along with decreased T cell immunophenotypic markers was observed in bone marrow lymphocytes of children with ITP in the present study. Further larger scale studies are recommended to confirm our findings, as precise mapping of the immunophenotype of lymphocytes in these patients would pave the road to improved diagnosis and treatment.

Entities:  

Keywords:  bone marrow lymphocytes; cellular immunology; childhood; immune thrombocytopenic purpura; immunophenotype

Mesh:

Year:  2014        PMID: 25007136     DOI: 10.3109/08880018.2014.927944

Source DB:  PubMed          Journal:  Pediatr Hematol Oncol        ISSN: 0888-0018            Impact factor:   1.969


  2 in total

1.  Atorvastatin improves bone marrow endothelial progenitor cell function from patients with immune-related hemocytopenia.

Authors:  Juan Qian; Qian Shen; Chun-Xia Yan; Hong Yin; Xin Cao; Zeng-Hua Lin; Yi-Feng Cai; Hong Liu
Journal:  Ann Transl Med       Date:  2021-07

2.  Identification of Candidate Biomarkers for Idiopathic Thrombocytopenic Purpura by Bioinformatics Analysis of Microarray Data.

Authors:  Samira Gilanchi; Hakimeh Zali; Mohammad Faranoush; Mostafa Rezaei Tavirani; Keyvan Shahriary; Mahyar Daskareh
Journal:  Iran J Pharm Res       Date:  2020       Impact factor: 1.696

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.